Deaths attributable to carbapenem-resistant enterobacteriaceae infections

Emerging Infectious Diseases

Volumn 20, Issue 7, 2014, Pages 1170-1175

  Falagas, Matthew E ^a,b   Tansarli, Giannoula S ^a   Karageorgopoulos, Drosos E ^a   Vardakas, Konstantinos Z ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CARBAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; KLEBSIELLA PNEUMONIAE CARBAPENEMASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ARTICLE; BACTEREMIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DATA BASE; DATA EXTRACTION; DEATH; DRUG RESISTANCE; ENTEROBACTERIACEAE INFECTION; HUMAN; INFECTION CONTROL; INFORMATION PROCESSING; KLEBSIELLA PNEUMONIAE INFECTION; META ANALYSIS (TOPIC); PATHOGENESIS; PUBLIC HEALTH; PUBLICATION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; CASE CONTROL STUDY; DRUG EFFECTS; ENTEROBACTERIACEAE; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MORTALITY; PATHOGENICITY; PHYSIOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84902781573     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2007.121004     Document Type: Article

References (37)

1. Hu F, Chen S, Xu X, Guo Y, Liu Y, Zhu D, et al. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China. J Med Microbiol. 2012;61:132-6. http://dx.doi.org/10.1099/jmm.0.036483-0
2. Zarfel G, Hoenigl M, Wurstl B, Leitner E, Salzer HJ, Valentin T, et al. Emergence of carbapenem-resistant Enterobacteriaceae in Austria, 2001-2010. Clin Microbiol Infect. 2011;17:E5-8. http:// dx.doi.org/10.1111/j.1469-0691.2011.03659.x
3. Daikos GL, Karabinis A, Paramythiotou E, Syriopoulou VP, Kosmidis C, Avlami A, et al. VIM-1-producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int J Antimicrob Agents. 2007;29:471-3. http://dx.doi.org/10.1016/ j.ijantimicag.2006.11.006
4. Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, Skoutelis A, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53:1868-73. http://dx.doi.org/10.1128/ AAC.00782-08
5. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20:440-58. http://dx.doi.org/10.1128/ CMR.00001-07
6. Agodi A, Voulgari E, Barchitta M, Politi L, Koumaki V, Spanakis N, et al. Containment of an outbreak of KPC-3-producing Klebsiella pneumoniae in Italy. J Clin Microbiol. 2011;49:3986-9. http:// dx.doi.org/10.1128/JCM.01242-11
7. Balkhy HH, El-Saed A, Al Johani SM, Francis C, Al-Qahtani AA, Al-Ahdal MN, et al. The epidemiology of the first described carbapenem- resistant Klebsiella pneumoniae outbreak in a tertiary care hospital in Saudi Arabia: how far do we go? Eur J Clin Microbiol Infect Dis. 2012;31:1901-9. http://dx.doi.org/10.1007/s10096-011- 1519-0
8. Borer A, Eskira S, Nativ R, Saidel-Odes L, Riesenberg K, Livshiz-Riven I, et al. A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenemresistant Klebsiella pneumoniae in southern Israel. Infect Control Hosp Epidemiol. 2011;32:1158-65. http://dx.doi. org/10.1086/662620
9. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother. 2011;55:2420-3. http://dx.doi.org/10.1128/AAC.01452-10
10. Gregory CJ, Llata E, Stine N, Gould C, Santiago LM, Vazquez GJ, et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol. 2010;31:476-84. http://dx.doi. org/10.1086/651670
11. Pereira GH, Garcia DO, Mostardeiro M, Ogassavara CT, Levin AS. Spread of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in São Paulo, Brazil. J Hosp Infect. 2011;79:182-3. http://dx.doi.org/10.1016/j.jhin.2011.05.023
12. Steinmann J, Kaase M, Gatermann S, Popp W, Steinmann E, Damman M, et al. Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro Surveill. 2011;16:19944.
13. Zhang R, Wang XD, Cai JC, Zhou HW, Lv HX, Hu QF, et al. Outbreak of Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae with high qnr prevalence in a Chinese hospital. J Med Microbiol. 2011;60:977-82. http://dx.doi.org/10.1099/ jmm.0.015826-0
14. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165:1430-5. http://dx.doi.org/10.1001/ archinte.165.12.1430
15. Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother. 2008;52:2680-2. http://dx.doi.org/10.1128/AAC.00158-08
16. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother. 2007;51:3026-9. http://dx.doi.org/10.1128/ AAC.00299-07
17. Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, et al. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother. 2009;64:348-52. http://dx.doi.org/10.1093/jac/dkp207
18. Zagorianou A, Sianou E, Iosifidis E, Dimou V, Protonotariou E, Miyakis S, et al. Microbiological and molecular characteristics of carbapenemase-producing Klebsiella pneumoniae endemic in a tertiary Greek hospital during 2004-2010. Euro Surveill. 2012;17:20088.
19. Chang HJ, Hsu PC, Yang CC, Kuo AJ, Chia JH, Wu TL, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect. 2011;44:125-30. http://dx.doi.org/10.1016/ j.jmii.2010.06.001
20. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180-5. http://dx.doi.org/10.1086/648451
21. Mouloudi E, Protonotariou E, Zagorianou A, Iosifidis E, Karapanagiotou A, Giasnetsova T, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase- producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 2010;31:1250-6. http://dx.doi.org/10.1086/657135
22. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099-106. http://dx.doi.org/10.1086/592412
23. Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007;60:1124-30. http://dx.doi.org/10.1093/jac/dkm356
24. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009;30:666-71. http://dx.doi.org/10.1086/598244
25. Jeon MH, Choi SH, Kwak YG, Chung JW, Lee SO, Jeong JY, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis. 2008;62:402-6. http://dx.doi.org/10.1016/j.diagmicrobio. 2008.08.014
26. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54-60. http://dx.doi.org/10.1111/j.1469-0691.2011.03478.x
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-58. http://dx.doi.org/10.1002/sim.1186
28. Gaviria D, Bixler D, Thomas CA, Ibrahim SM, Kallen A, Limbago B, et al. Carbapenem-resistant Klebsiella pneumoniae associated with a long-term-care facility-West Virginia, 2009-2011. MMWR Morb Mortal Wkly Rep. 2011;60:1418-20.
29. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028-33. http://dx.doi.org/10.1128/AAC.01020-07
30. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798-803. http://dx.doi.org/10.1111/ j.1469-0691.2011.03514.x
31. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 2011;6:653-66. http://dx.doi.org/10.2217/fmb.11.49
32. Woodford N, Turton JF, Livermore DM. Multiresistant Gramnegative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011;35:736-55. http://dx.doi.org/10.1111/j.1574-6976.2011.00268.x
33. García-Sureda L, Doménech-Sánchez A, Barbier M, Juan C, Gascó J, Albertí S. OmpK26, a novel porin associated with carbapenem resistance in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:4742-7. http://dx.doi.org/10.1128/AAC. 00309-11
34. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother. 2007;60:913-20. http://dx.doi. org/10.1093/jac/dkm318
35. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66:401-14. http://dx.doi.org/10.1016/ j.jinf.2012.10.028
36. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extendedspectrum b-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67:1311-20. http://dx.doi.org/10.1093/jac/dks065
37. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth- informational supplement. Document M100-S20 Vol. 30 N. Wayne (PA): The Institute; 2010.